The p230 variant of this protein is associated with a more neutrophilic phenotype, and its other variants are p210 and p190, which can often be a splice variant.
The p230 variant of this protein is associated with a more neutrophilic phenotype, and its other variants are p210 and p190, which can often be a splice variant. The cooperation of this protein with NUP98/HOXA9 in a mouse strain is a useful model of how this protein can help drive a "blast crisis". Tasigna and Sprycel are second-generation drugs targeting this protein, though they remain somewhat blunted against P-loop mutations in it. This protein acquires resistance via a T315I mutation, though it remains susceptible to Iclusig. One part of this protein is homologous to a protein found in the (*) Abelson murine leukemia virus. This protein is expressed by a structure created by a 9 to 22 translocation, and is targeted by a small molecule originally called STI-571, and is now called imatinib mesylate. For 10 points, name this protein that drives pathogenesis of chronic myelogenous leukemia, which is the product of the Philadelphia chromosome.
The p230 variant of this protein is associated with a more neutrophilic phenotype, and its other variants are p210 and p190, which can often be a splice variant.
BCR-ABL fusion protein [prompt on "Philadelphia chromosome"]